X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nuvaxovid XBB.1.5 (NVX-CoV2601) is an updated version of Novavax's prototype COVID-19 vaccine (NVX-CoV2373) formulated to target the Omicron XBB.1.5 subvariant. It is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID.
Lead Product(s): NVX-CoV2601
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Nuvaxovid XBB.1.5 (NVX-CoV2601) is an updated version of Novavax's prototype COVID-19 vaccine (NVX-CoV2373) formulated to target the Omicron XBB.1.5 subvariant. It is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID.
Lead Product(s): NVX-CoV2601
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid XBB.1.5
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Nuvaxovid (NVX-CoV2601) is an SARS-CoV-2 spike protein inhibitor vaccine, which is currently being evaluated for individuals 12 years of age and older with COVID-19 infection via intramuscular injection.
Lead Product(s): NVX-CoV2601
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Lead Product(s): NVX-CoV2601
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Lead Product(s): NVX-CoV2601
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
The R21/Matrix-M component is a proprietary saponin-based adjuvant vaccine developed by Novavax and licensed to the Serum Institute for use in endemic countries, which is indicated for the preventing of malaria.
Lead Product(s): R21/Matrix-M Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Lead Product(s): NVX-CoV2373
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Lead Product(s): NVX-CoV2373
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
Under the partnership, SK bioscience will explore potential future collaborations with Novavax such as utilizing the Novavax's adjuvant, Matrix-M for advancing protein-based vaccines inclding, Nuvaxovid (NVX-CoV2373) to prevent COVID-19.
Lead Product(s): NVX-CoV2373,Matrix-m1
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: SK Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 08, 2023
Details:
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Lead Product(s): NVX-CoV2373
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
